Terumo is expanding its presence in Turkey with the acquisition of a distributor of blood bank-related medical equipment.
Terumo BCT, the blood-focused division of the Japanese med tech giant, has signed a deal with the U.S. Department of Defense to share costs in the development of a device that can treat donated blood used in emergency transfusions.
Unsatisfied with all its HeartMate success, Thoratec is spending cash to further its share of the left ventricular assist device market, shelling out up to $56.5 million for Terumo's investigational DuraHeart II.
Terumo is planning to hire 416 people in Northern Ireland, expanding the R&D operations at a plant that produces blood transfusion technologies.
Terumo has prevailed in a patent spat with Vascular Solutions, and the latter company will stop manufacturing and selling a device Terumo said infringed on its intellectual property.
BSD Medical inked a wide-ranging deal with Japanese med tech giant Terumo to distribute one of its signature tumor ablation devices in Europe, Western Asia and North Africa.
Terumo's drug-eluting stent, Nobori, nabbed a bit of Abbott Laboratories' Xience glory as it proved in a large study to be just as effective as the top-selling American brand.
The American College of Cardiology's annual scientific summit made for a busy weekend in the medical device world. We've rounded up some highlights from the annual expo.
Terumo is striking out on its own in the urology market, announcing that it will terminate its distribution deal with Boston Scientific and take on U.S. sales of its Glidewire Hydrophilic Guidewire products.
Switzerland's Biosensors International will work with Japan's Terumo to promote that company's Nobori drug-eluting stent in Japan.